<code id='7EAA3DF2DF'></code><style id='7EAA3DF2DF'></style>
    • <acronym id='7EAA3DF2DF'></acronym>
      <center id='7EAA3DF2DF'><center id='7EAA3DF2DF'><tfoot id='7EAA3DF2DF'></tfoot></center><abbr id='7EAA3DF2DF'><dir id='7EAA3DF2DF'><tfoot id='7EAA3DF2DF'></tfoot><noframes id='7EAA3DF2DF'>

    • <optgroup id='7EAA3DF2DF'><strike id='7EAA3DF2DF'><sup id='7EAA3DF2DF'></sup></strike><code id='7EAA3DF2DF'></code></optgroup>
        1. <b id='7EAA3DF2DF'><label id='7EAA3DF2DF'><select id='7EAA3DF2DF'><dt id='7EAA3DF2DF'><span id='7EAA3DF2DF'></span></dt></select></label></b><u id='7EAA3DF2DF'></u>
          <i id='7EAA3DF2DF'><strike id='7EAA3DF2DF'><tt id='7EAA3DF2DF'><pre id='7EAA3DF2DF'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:534
          he exterior of the U.S. Capitol building is seen at sunrise
          Sarah Silbiger/Getty Images

          WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

          The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

          advertisement

          • One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
          • Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
          • A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

          The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          Sanofi strikes deal with Novavax, boosting the vaccine maker
          Sanofi strikes deal with Novavax, boosting the vaccine maker

          NICOLASMAETERLINCK/BELGAMAG/AFPviaGettyImagesLONDON—Novavax,thebeleagueredmakerofaCovid-19vaccine,ju

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          In shift, Texas to cover initial consult for Afghan baby's gene therapy

          MichaelGonzalez/APThePashaifamilyofDallasonThursdaygotsomegoodnews,butnotexactlythenewstheyhadspentt